China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Qinhuangdao Zizhu received the World Health Organization prequalification certificate for its levonorgestrel active pharmaceutical ingredient.
Levonorgestrel is a fast-acting contraceptive drug, according to a Thursday filing with the Shanghai bourse.
The certification confirms the API meets WHO quality standards, providing a key entry qualification for international procurement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。